Frovocimab is used to inhibit the binding of PCSK9 to the LDL receptor (LDLR), thereby preventing PCSK9-mediated degradation of LDLR and promoting normal proteolytic cleavage of bound, intact PCSK9; this mechanism enhances LDL cholesterol clearance and is applied in the research of lipid-lowering therapies.